Author + information
- Received March 17, 2020
- Accepted March 17, 2020
- Published online March 19, 2020.
- Elissa Driggin, MDa,∗,
- Mahesh V. Madhavan, MDa,b,∗,
- Behnood Bikdeli, MD, MSa,b,c,
- Taylor Chuich, PharmDa,
- Justin Laracy, MDa,
- Giuseppe Bondi-Zoccai, MD, MStatd,e,
- Tyler S. Brown, MDf,
- Caroline Der Nigoghossian, PharmDa,
- David A. Zidar, MD, PhDg,
- Jennifer Haythe, MDa,
- Daniel Brodie, MDa,
- Joshua A. Beckman, MDh,
- Ajay J. Kirtane, MD, SMa,b,
- Gregg W. Stone, MDb,i,
- Harlan M. Krumholz, MD SMj,c,i,k and
- Sahil A. Parikh, MDa,b,# ()
- aNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York
- bClinical Trials Center, Cardiovascular Research Foundation, New York, New York
- cCenter for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut
- dDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
- eMediterranea Cardiocentro, Napoli, Italy
- fMassachusetts General Hospital, Boston, Massachusetts
- gCase Western Reserve School of Medicine, Louis Stokes Cleveland VAMC, Cleveland, Ohio
- hVanderbilt University Medical Center, Nashville, Tennessee
- iIcahn School of Medicine at Mount Sinai, New York, New York
- jSection of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
- kDepartment of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut
- ↵#Corresponding Author: Sahil A. Parikh, MD Columbia University Irving Medical Center, NewYork-Presbyterian Hospital 161 Fort Washington Ave, 6th Floor, New York, NY 10032 .
The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.
↵∗ The first two authors contributed equally to this manuscript
Disclosures: Dr. Madhavan reports being supported by an institutional grant by the National Institutes of Health/ National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center (T32 HL007854). Dr. Bikdeli reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to a specific type of IVC filters. Dr. Brodie receives research support from ALung Technologies, he was previously on their medical advisory board. He has been on the medical advisory boards for Baxter, BREETHE, Xenios and Hemovent. Dr. Kirtane reports Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Philips, ReCor Medical. Personal: conference honoraria and travel/meals only. The remaining authors report no relevant conflicts of interest. Dr. Stone has received speaker or other honoraria from Cook, Terumo, QOOL Therapeutics and Orchestra Biomed; serving as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme; and equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, Valfix. Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the U.S. Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data enterprise. Dr Parikh reports institutional grants/research support from Abbott Vascular, Shockwave Medical, TriReme Medical, Sumodics, Silk Road, Medical, and the NIH; consulting fees from Terumo and Abiomed; and Advisory Board participation for Abbott, Medtronic, Boston Scientific, CSI, and Philips. The other others do not report any relevant conflicts of interest.
- Received March 17, 2020.
- Accepted March 17, 2020.